>> > > HELLO, EVERYBODY
WELCOME TO THE UVA MEDICAL CENTER HOUR. I'' M JUSTIN
MUTTER WITH THE CENTER FOR WELLNESS, LIBERAL ARTS AS WELL AS ETHICS. WE'' RE EXCITED TO BRING YOU TODAY'' S EVENT IN COLLABORATION WITH THE DEPARTMENT OF MEDICINE AND DEPARTMENT OF INFECTIOUS ILLNESS IN INTERNATIONAL HEALTH AND WELLNESS. THE ANNUAL HAYDEN-FARR LECTURE AS WELL AS EPIDEMIOLOGY MARKS A.
CRITICAL OPPORTUNITY TO TIME OUT. ESPECIALLY IN THE MIDDLE OF OUR ONGOING PANDEMIC AND TO.
THINK TOGETHER ABOUT THE PAST, EXISTING AS WELL AS FUTURE OF.
THE GENERAL PUBLIC'' S HEALTH AND WELLNESS. TODAY'' S SESSION IS OFFERED.
IN ZOOM WEBINAR LAYOUT AS WELL AS WE WELCOME OUR LOTS.
GUESTS, BOTH INSIDE AND BEYOND THE COLLEGE OF.
VIRGINIA, AND WHEN THE MOMENT COMES FOR CONVERSATION AND.
CONCERNS COMPLYING WITH TODAY'' S LECTURE, WE INVITE TO YOU.
SUBMIT YOUR QUESTIONS VIA THE Q&A TAB AT THE BASES OF.
YOUR ZOOM DISPLAY. INFORMATION ABOUT CONTINUING.
EDUCATION AND LEARNING CREDIT REPORT IS ALSO AVAILABLE ON THE OPENING AND.
CLOSING SLIDES WHICH YOU WILL SEE TOWARD THE ON YOUR.
ZOOM SCREEN. IT IS NOW MY OPPORTUNITY TO WELCOME TO OUR.
MEDICAL CENTER HR PHASE, OUR MODERATOR FOR TODAY, THAT.
LIKE THE DIFFERENTIATED AUDIO SPEAKER, HE WILL CERTAINLY INTRODUCE.
REALLY NEEDS NO INTRODUCTION.
DR. COSTI.
SIFRI IS TEACHER OF MEDICINE AND ENDOWED CHAIR.
IN CONTAGIOUS CONDITION HERE AT UVA KNOWN WELL TO MANY.
PARTICIPANTS THROUGHOUT UVA AS EXTRAORDINARY LEADER IN.
INFECTION CONTROL BEFORE AND THROUGHOUT THE PANDEMIC, DR. SIFRI IS THE MEDICAL SUPERVISOR OF UVA'' S. IMMUNOCOMPROMISED INFECTIOUS DISEASES PROGRAM. AN.
GLOBALLY IDENTIFIED SCHOLAR IN MOLECULAR.
PUBLIC HEALTH AND ALSO TRANSITION OF MULTIRESISTANT MICROORGANISMS.
WE ARE HONORED TO HAVE DR. SIFRI AS OUR MEDIATOR FOR.
TODAY'' S OCCASION.
>> TODAY ' S EVENT. > > THANK YOU, JUSTIN. THAT ' S REALLY CHARITABLE OF YOU. THIS IS TRULY AN HONOR AND PLEASURE TODAY. SO I'' D LIKE. TO BEGIN BY SAYING THAT I CAN'' T CONSIDER A BETTER. SPEAKER THAN TODAY ' S AUDIO SPEAKER FOR THE TENTH ANNUAL HAYDEN.
FARR LECTURE. BRIEFLY, FRED HAYDEN AND ALSO BARRY FARR, THAT.
THIS LECTURE COLLECTION RECOGNIZES, ARE LEADERS OF.
VIROLOGY AND ALSO EPIDEMIOLOGY.FRED JOINS United States TODAY AND ALSO MANY. OF YOU RECOGNIZE BARRY FARR PASSED AWAY SEVERAL YEARS. AGO BUT A LEADING VOICE IN PUBLIC HEALTH AS WELL AS INFECTION. CONTROL. THE LECTURE TODAY IS BEING PRESENTED BY.
ROCHELLE WALENSKY THAT NEEDS NO INTRODUCTION AS THE.
DIRECTOR OF THE CDC AND I ' LL TALK A LITTLE
LITTLE BIT EVEN MORE ABOUT. HER BIO IN A SECONDLY. I ' D LIKE TO
TAKE A MINUTE,.'THOUGH, FIRST AND ACKNOWLEDGE DR. JACK WALTNY. WHO MADE THIS TALK SERIES FEASIBLE AS WELL AS SPECIAL MANY THANKS. AND ALSO SHOUTOUT TO CAMERON WEBB THAT HELPED FACILITATE THIS. CONVERSATION TODAY. SO THANK YOU, CAMERON.
WHAT. REQUIRES NO INTRO. SHE DID TRAINING AT JOHNS. HOPKINS COLLEGE.
AFTER HOPKINS SHE SIGNED UP WITH BRIGHAM. LADIES ' S MEDICAL FACILITY FOR IB
FELLOWSHIP TRAINING WHERE. SHE ALSO OBTAINED HER LEVEL IN PUBLIC HEALTH AND WELLNESS AND SHE. AFTER THAT JOINED THE PROFESSORS AT MASS GENERAL AND PROMPTLY.
ASCENDED THE RANKS COMING TO BE A WORLD SPECIALIST IN UTILIZING.
REALLY EVIDENCE-BASED POLICY AND METHOD TO EDUCATE HIV.
CARE, FROM HIV TESTING AND SCREENING AS WELL AS PREP AND A WHOLE.
HOST OF OTHER PROBLEMS DURING HER PROFESSION.
ADDITIONALLY,.
SHE WAS AN EXTREMELY VOCAL, PASSIONATE ADVOCATE,.
ENTHUSIASTIC CARE OF HIV PATIENTS AND ALSO LIKEWISE, I BELIEVE,.
SIMPLY REALLY A NOTABLE STANDOUT IN UNDERSTANDING.
THE ISSUES AROUND GENDER AND ALSO EQUITY IN CLINICAL TREATMENT AS.
WELL AS CLINICAL STUDY. IN 2017, DR. WALENSKY WAS.
NAMED SUPERVISOR, PRIMARY OF THE INFECTIOUS CONDITION DIVISION.
AT MASS GENERAL MEDICAL FACILITY AS WELL AS AS WE KNOW, IN LATE OF 2020.
WAS ASKED BY HEAD OF STATE BIDEN TO TAKE THE HELM OF THE CDC. SHE WAS AN IMPORTANT AND ALSO LEADING VOICE IN THE EARLY.
CARE OF PATIENTS THROUGHOUT THE COVID PANDEMIC. OF COURSE,.
BOSTON WAS AMONG THE CITIES THAT TRULY WAS FIRST.
INFLUENCED BY COVID AND ALSO HER EXPERIENCE AS BOTH FRONTLINE.
FACILITIES AND LEADING A WORLD-RENOWNED ID PROGRAM.
VIA THE BEGINNING OF THE PANDEMIC WERE.
EDUCATIONAL FOR EVERYBODY WHO ENCOUNTERED THE SAME ADJUSTMENTS.
IN THE NEXT NUMBER OF MONTHS AND ALSO ALONG WITH THE.
PANDEMIC, TIPPING OUTSIDE OF CLINICAL TREATMENT, SHE WAS AN.
CRUCIAL SUPPORTER OF UNDERSTANDING HOW TO PROVIDE.
COLLEGES AND AIDED STUDENTS RETURN TO CLASSROOM.
FROM DESIGNING SYSTEMS AND MODELING RESEARCH STUDIES TO PROGRAM HOW.
STUDENTS COULD RETURN BACK TO IN-PERSON DIRECTION.
BEFORE THE ROLLOUT OF VACCINES AND ALSO EACH TIME WHEN.
THE MAJORITY OF PEOPLE HAD ACTUALLY NOT YET RUN INTO COVID.
SO IT.
WAS REALLY JUST AN OUTRIGHT HONOR AS WELL AS PLEASURE TO HAVE.
DR. WALENSKY SIGN UP WITH US TODAY. SHE'' LL BE GIVING TODAY'' S. LECTURE AND ALSO HOPEFULLY AT THE TIME, WE WILL HAVE A LITTLE.
LITTLE BIT OF TIME FOR Q&A. ROCHELLE. ROCHELLE. >> > > TERRIFIC. THANK YOU, COSTI. FIRST, ALLOW ME TO SAY WHAT AN HONOR AND PRIVILEGE IT IS.
FOR ME TO PROVIDE THIS TALK AND FOR THE INDIVIDUALS IT FORMALITY.
AND HOW SO MUCH OF SCIENTIFIC RESEARCH IS DEPENDING ON THE SHOULDERS.
OF GREATNESS AHEAD OF YOU. SO I IDENTIFY THAT I'' M. DOING SO IN THE CONTEXT OF THIS LECTURE. I DO ADDITIONALLY.
WANT TO LET FOLKS KNOW THAT SOMETIMES EXCELLENT THINGS.
OCCUR IN TINY LITTLE FELLOWS ROOMS AND ALSO ONE OF.
THOSE TERRIFIC POINT IS I HAD THE FANTASTIC ADVANTAGE OF.
SATISFYING COSTI DURING MY FELLOWSHIP. KEEP SOME.
ACTUALLY GREAT FRIENDSHIPS AS WELL AS ACTUALLY EXCELLENT ASSOCIATE AS WELL AS.
COLLABORATIONS. I AM GOING >> > > PERFECT, WONDERFUL.
THIS IS. REALLY AMONG MY FAVE AUDIENCES WHICH IS SORT.
OF HOME TO MY ACADEMIC AUDIENCES, WHICH IS ARE.
KNOWN AS WELL AS FAMILIAR TO ME AND REALLY, AGAIN, WHAT A WONDERFUL.
PLEASURE IT IS FOR ME TO BE BELOW WITH YOU.
I THOUGHT I.
WOULD JUST SPEND THE NEXT 50 MINUTES APPROXIMATELY TALKING ABOUT.
KIND OF CDC'' S ACTION-ORIENTED RESPONSE TO. PUBLIC WELLNESS AND ALSO SOME OF THINGS THAT I CONSIDER.
ON A DAILY BASIS AND THE INFORMATION THAT I CONSIDER EACH DAY AND ALSO KIND.
OF MAYBE OFFERING YOU A HOME WINDOW RIGHT INTO SOME OF THE MOMENTS,.
A FEW OF THE HARDEST MOMENTS FOR THIS PANDEMIC FOR ME AND ALSO.
SOME OF THE CHALLENGES AND CHOICES THAT WE HAD TO.
MAKE AT CDC. SO AMONG THE THINGS I CHECK OUT EVERY.
MORNING THESE INFORMATION HAD BEEN COMING IN ON A DAILY.
CADENCE. THEY'' RE NOW COMING IN ON A WEEKLY TEMPO, IS.
THE STATE OF OUR COVID-19 PANDEMIC, OUR OVERALL CASES,.
CONFIRMED COVID-19 HOSPITALIZATIONS, AND ALSO FATALITIES.
TO DAY. WE TAKE A LOOK AT THESE AS A SEVEN-DAY DAILY AVERAGE.
AND AFTER THAT WE CHECK OUT THESE AS A WEEK-ON-WEEK MODIFICATION, AND.
FORTUNATELY, THOSE WEEK-ON-WEEK ADJUSTMENTS.
REMAIN TO BE ENVIRONMENT-FRIENDLY, BUT WE HAVE SEEN LOTS, LOTS OF DAYS.
AND ALSO WEEKS WHERE THOSE WERE RED AND INCREASING.
I.
THINK OUR CIRCUMSTANCES, CONFIRMED HOSPITALIZATIONS AND DEATHS,.
THOUGH NOWHERE NEAR DOWN WHERE I WOULD LIKE THEM TO.
BE, ARE LESS THAN WE'' VE SEEN IN ALMOST ANY POINT.
THROUGHOUT THIS PANDEMIC. ONE OF THINGS THAT WE HAVE.
HEARD TIME AND ALSO TIME ONCE MORE IS HOW WELL CANISTER WE COUNT ON.
THOSE SITUATION NUMBERS, AS WELL AS I BELIEVE THAT THIS IS QUITE.
VITAL. HAD IS A CHART OF SCREENING HABITS, AS WELL AS.
WHAT WE CANISTER SEE AND THIS IS PCR TESTING BEHAVIORS. WHAT.
WE CANISTER SEE IN BENCH GRAPH IN TIME. TIME IS ON THE.
HORIZONTAL GAIN ACCESS TO. YOU TIN SEE THE PCR TESTS HAVE.
REDUCED WITH TIME. THERE WAS A TIME DURING THE.
OMICRON PHASE, THAT BIG PEAK WHERE WE WERE SCREENING ABOUT.
3 MILLION PCR TESTS EACH DAY. WE'' RE NOW IN THE 300 TO.
400,000 PCR EXAMINATIONS PER DAY. THEY DO OFFER United States A HELPFUL.
HOME WINDOW IN TERMS OF TRENDS. AMONG MY FAVORITE QUOTES BY.
SOMEBODY IN OUR INCIDENCE MANAGEMENT GROUP SAID YOU.
DON'' T REQUIRED TO TRUST THE RAINDROPS TO KNOW HOW HARD.
IT'' S RAINING. I DO THINK THAT WE DID MAKE A CONSCIOUS.
CHOICE IN COOPERATION WITH OUR PUBLIC WELLNESS.
COMPANIONS AS TO WHETHER WE NEEDED TO MATTER EVERY.
ANTIGEN TEST BEING DONE REALIZING THAT ANTIGEN EXAMINATIONS.
MAY SWIFTLY REPLACE THE PCR SCREENING DONE.
THERE WAS A.
GREAT DEAL OF CONVERSATION ABOUT THAT CHOICE. WE DO RECOGNIZE.
THE TESTING BEHAVIORS HAVE ACTUALLY TRANSFORMED.
THIS IS EQUALLY AS WE HAVE REDUCED OUR PRC SCREENING. THIS IS AN MMWR THAT REALLY JUST LOOKED AT ANTIGEN.
EXAMINING CHANGE FROM AUGUST '' 21 TO MARCH ' 22 TO SEE THE. SCALE OF ANTIGEN SCREENING, BOTH IN THE POPULACE.
OVERALL, SHOWN BY THAT DARK LINE AT THE BASE TOO.
AS THE AMONGST PEOPLE WHO ARE ASYMPTOMATIC, THE LIGHTER IN WEIGHT.
LINE AND ALSO THE MIDDLE LINE AMONGST INDIVIDUALS THAT ARE.
SYMPTOMATIC. SO WE ARE FOLLOWING THE CASE FAD,.
WE DO FULLY RECOGNIZE WE'' RE NOT CAPTURING EVERY RAINDROP.
AND ALSO THAT WE ARE REALLY USING THOSE CASES TO CAPTURE.
TRENDS. SO WHAT I ASSUMED I MIGHT DO IS KIND OF BRING.
YOU INTO THE SURGE OF OMICRON AND REWIND TO WHAT WAS.
LITERALLY THANKSGIVING DAY.WE HAD ALL BEEN WORKING EXTREMELY.
TOUGH, ALL KIND OF SEEKING THAT BREAK AND MY OVEN.
MITTS GOT ON, AND ALSO I WAS REALLY TRYING TO PUT MY.
PHONE ASIDE. I WILL TAKE THE TURKEY OUT OF THE.
STOVE AND I OBTAINED ABOUT SIX CALLS FROM THE WHITE HOUSE. SO THE MOMENT WAS NOT TO HAVE TURKEY, OBVIOUSLY. THE MOMENT.
WAS REALLY TO TALK ABOUT THAT THERE WAS A NEW VARIANT IN.
SOUTH AFRICA THAT WAS PROMPTING POTENTIAL.
CONSTRAINTS TO INTERNATIONAL TRAVELING. LITERALLY, IT WAS THANKSGIVING DAY THAT WE.
WERE FIRST HEARING ABOUT THIS. IT WAS COMING OVER.
TWITTER. IT WAS QUICKLY BEING CLASSIFIED AS THE.
OMICRON VARIANT OF ISSUE BY THE WHO BY THE NEXT DAY,.
AND WE GOT ON THE PHONE WITH ASSOCIATES FROM SOUTH.
AFRICA, AND AMONG THE EXCELLENT PRESENTS OF SCIENCE IS HOW.
THOSE COWORKERS LINK INTERNATIONAL BORDERS AND ALSO.
TIME, ROOM, AND PATHOGEN.SO COWORKERS I HAVE. LITERALLY FUNCTIONED WITHIN HIV FOR DECADES, NOW WE GOT ON. PHONE WITH ON THANKSGIVING TALKING ABOUT OMICRON. SO. THESE WERE SOME OF THE INFORMATION THAT WERE APPEARING OF. SOUTH AFRICA, AS WELL AS YOU TIN SEE, IF YOU JUST MAP THESE.
VARIOUS WAVES IN DAYS SHOWN ON THE VERTICAL.
ACCESS, AS WELL AS– ON THE STRAIGHT AXIS AS WELL AS THE.
VARIETY OF CASES OF COVID-19 ON THE VERTICAL AXIS, YOU. SEE WHAT WAS TAKING PLACE WITH OMICRON WAS VERY DIFFERENT. FROM THESE OTHER WAVES, THE ALPHA WAVE, BETA WAVE, AND
. DELTA WAVE, AND YOU CAN SEE THIS ENORMOUS, STEEP SURGE,. EXTREMELY FAST SURGE IF WAS OCCURRING WITH.
OMICRON. SOUTH AFRICA WAS THE FIRST TO FIND THE.
ALTERNATIVE. ALTHOUGH, IT MAY EFFECTIVELY HAVE BEEN
PRESENT. IN OTHER NEIGHBORING QUESTIONS THAT DIDN ' T HAVE. THE ABILITY TO GENO KIND OR DO GENOMIC SEQUENCE AND WHAT.
WAS ALSO QUICKLY BECOMING AVAILABLE WERE INFORMATION FROM THE.
U.K. WHICH WAS FOLLOWING THIS VARIABLE PRIOR TO WE HAD.
IT, DEMONSTRATING THAT FAMILY TRANSMISSION FROM.
OMICRON WAS 3.2 TIMES THAT OF WHAT WAS HAPPENING OR.
WHAT HAD OCCURRED WITH DELTA, WHICH EARLY.
PRELIMINARY SEARCHINGS FOR FROM NUMEROUS SOURCES WERE.
RECOMMENDING THAT OMICRON HAD A TRANSMISSION ADVANTAGE.
COMPARED TO DELTA. SO WE HAVE WHAT WE CALL A VERSION.
PLAYBOOK AND ALSO EVERY TIME A NEW VERSION EMERGES, AMONG. THE CONCERNS THAT WE ASK IS, IS IT MORE SEVERE? THAT IS IT MORE EXTREME IN? HOW DO OUR DIAGNOSTICS WORK? HOW DO OUR MEDICAL COUNTERMEASURES WORK? HOW. DO OUR VACCINES WORK? SIMPLY AT THANKSGIVING TIME, AROUND. THIS MOMENT WAS WHEN WE WERE FIRST ESTABLISHING OUR CENTER.
FOR FORECASTING AND ALSO OUTBREAK ANALYTICS. THIS IS A FACILITY OFFICIALLY RELEASED AT THE WHITE HOME.
LAST APRIL. WE WERE STARTING TO COLLECT A LEAN.
AND ALSO MIGHTY TEAM LED BY MARK LIPSICH AND DYLAN GEORGE.
WHERE THIS FACILITY HAD THE MISSION OF GETTING.
FORECASTS AND ALSO ANALYSES TO ASSISTANCE OUTBREAK.
PREPAREDNESS, UNDERSTANDING AND ALSO INTERACTING
THE DESIGN. OUTCOMES AND ALSO THE NEEDS THAT CHOICE MAKERS HAD IN THE. MINUTE, JUST WHEN WE SAW THAT THERE COULD BE
AN. IMPENDING, NEW VARIATION AND TO ASSISTANCE CURRENT.
DEVELOPMENT TO BOOST EPISODE AS WELL AS FORECAST.
ANALYSES. SO AMONGST THE FIRST TEAMS THAT WE INVOLVED.
WITH WAS OUR CFA GROUP, AND WE ASKED A PAIR OF.
QUESTIONS CONCERNING HOW THIS COULD GO. THESE ARE.
SENSITIVITY EVALUATIONS, MODELING WHAT COULD
HAPPEN.
WITH AVAILABLE DATA FROM BOTH SOUTH AFRICA AND ALSO THE.
U.K. CURRENTLY THE FOUR BOXES REPRESENT 2 DIFFERENT–.
TWO-BY-TWO EVALUATION OF TWO DIFFERENT PARAMETERS. TRANSMISSIBILITY AND IMMUNE GETAWAY. THOSE ARE FUNDAMENTAL. TO THE NEW VARIANT, THE OMICRON VERSION.
HOW WILL. THEY INFLUENCE AND HOW MANY CASES WE WOULD HAVE OVER.
TIME? WHAT YOU CAN SEE IS HOW TRANSMISSIBILITY,.
HIGHEST CAPE IN THE UPPER, LEFT-HAND BOX.
LOW. TRANSMISSIBILITY, LOW LEAVE IN THE LOWER, LEFT-HAND BOX,.
AND AFTER THAT LOW GET AWAY IN BOTH BOXES ON THE RIGHT. WHAT YOU CONTAINER ALSO SEE RIGHT HERE IS THE SENSITIVITY ANALYSES.
ON WHAT OCCURS WITH REGARD TO HOW WE RESPOND. WHAT.
TAKES PLACE WITH OUR REDUCTION REACTION ALONG WITH WHETHER.
WE CAN BOOST, USE OUR BOOSTING DEVICES, IF WE.
CONTAINER BOOST PEOPLE FAST ENOUGH IN ORDER TO SHOT AS WELL AS AVERT A.
MAJOR OMICRON WAVE. I ASSUME YOU CAN SEE IN THESE SLIDES.
THAT THE– THE TRANSMISSIBILITY AS WELL AS IMMUNE.
RUN AWAY WERE QUITE EVEN MORE DETERMINING WHAT WAS GOING TO.
OCCUR WITH THIS VARIANT THAN OUR REDUCTION AND ALSO OUR.
IMPROVING INITIATIVES.
ALTHOUGH, YOU CAN SEE THE CONTOUR SHIFT.
DESCENDING AND ALSO TO THE RIGHT IF WE WERE ABLE TO DO MORE WITH.
REDUCTION, IF WE WERE ABLE TO DO MORE WITH BOOSTING. THIS WAS AMONG THE EARLY UNDERSTANDINGS THAT OUR CFA.
DESIGNING PERMITTED US TO DEMONSTRATE, BUT GIVEN THAT.
OUR DATA WERE BEGINNING TO ARISE THAT WE MAY HAVE HIGH.
TRANSMISSIBILITY AND ALSO HIGH IMMUNE ESCAPE, WE WERE.
EXPECTING A QUITE HUGE WAVE THAT WAS REALLY AT OUR.
FEET. AMONG THE OTHER POINTS THAT WAS BEGINNING TO.
COME CLEAR FROM OUR U.K. COLLEAGUES AS WELL AS REALLY OF THE.
GAUTENG PROVINCE, AND THIS IS THE INFORMATION FROM GAUTENG,.
AND ALSO THESE ARE ISSUE FATALITIES FROM OMICRON. IF YOU.
TAKE A LOOK AT THESE VARIOUS WAVES THAT OCCURRED. WAVE.
2, WAVE THREE. THE PRELIMINARY WAVE, WAVE 2 AS WELL AS.
WAVE 3. YOU SEE THESE PEAKS OF CIRCUMSTANCES SHOWN IN BLUE,.
HOSPITAL STAYS DISPLAYED IN GREEN AS WELL AS DEATHS SHOWN IN.
ORANGE APPEARANCE LIKE THEY'' RE ESSENTIALLY MATCHING ONE.
ANOTHER. YET WHAT WAS OCCURRING WITH OMICRON EARLY.
ON, YOU COULD SEE THIS LARGE NUMBER OF CASES, A.
HIGH NUMBER OF HOSPITALIZATIONS, ALTHOUGH.
CERTAINRY NOT THE VERY SAME MAGNITUDE AS INSTANCES AND EVEN.
LOWER MAGNITUDE IN REGARDS TO THE VARIETY OF DEATHS.
SO.
THIS WAS WHAT WE WERE LEARNING IN REAL TIME, WEEK.
AFTER WEEK AS WE HAD SCIENTIFIC CALLS ON SUNDAY.
MORNING AND 8:00 WITH OUR SOUTH AFRICA COWORKERS. HERE IS HOW WE IN THE UNITED STATES WERE MAPPING OUR.
OMICRON VERSION. WE HAD OUR FIRST CASE THAT WAS.
DOCUMENTED. I REMEMBER I WAS IN THE WHITE HOUSE AT.
THE TIME. THERE WAS A LIVE PRESS INSTRUCTION ON DECEMBER.
First OF 2021. AS WELL AS FOR THE WEEK, YOU TIN SEE THIS.
ENORMOUS RISE. SO IF DELTA VARIANTS ARE SHOWN IN ORANGE.
AS WELL AS OMICRON VARIANTS ARE SHOWN IN PURPLE, YOU TIN SEE.
THIS MASSIVE, SPEEDY SURGE IN THE NUMBER OF VERSIONS, THE.
PERCENTAGE OF VARIANTS THAT WERE OMICRON. SUCH THAT IN.
THAT SINGLE MONTH TIME PERIOD WE WERE ABOUT 95% OF.
OUR VARIANTS BEING OMICRON. ONCE MORE, AMONG THE INQUIRIES.
THAT KEPT SHOWING UP AS WELL AS KEPT BEING ASKED OF United States IS, WILL.
OMICRON BE EVEN MORE SEVERE? AND MANAGING FOR THAT AND ALSO.
UNDERSTANDING THAT WAS A REALLY CHALLENGING CONCERN. I.
HAD THE WONDERFUL BENEFIT OF CALLING ONCE AGAIN ON OUR CFA.
COWORKERS, ONCE AGAIN, THIS SMALL AND ALSO MIGHTY GROUP TO TRY.
AND SCOPE THE LANDSCAPE FOR HOW WE WERE GOING TO RESPONSE.
THAT QUESTION WITH DATA THROUGHOUT THE UNITED STATES. ONE OF THE FIRST QUESTIONS IS ESPECIALLY IN THAT DURATION.
OF TIME BECAUSE DECEMBER AMOUNT OF TIME, WE DIDN'' T. HAVE REAL-TIME GENOMIC SEQUENCING OF EVERY INDIVIDUAL.
IN THE UNITED STATES THEREFORE SOME WERE DOING ANALYSES.
THAT CLAIMED, WELL, AND IT'' S OVER 50 %OF INDIVIDUALS IN A.
REGION OR SERIES REMAINS IN An AREA, WE'' LL PHONE CALL THAT.
MOSTLY OMICRON. WE DID LEVERAGE THE KAISER THE.
PERMIANTY HEALTH SYSTEM BECAUSE IT WAS A CLOSED.
SYSTEM AND SINCE THEY WERE USING THE TAC PCR, BECAUSE.
OF THAT THEY COULD DISTINGUISH TARGET FAILURE.
FROM NON-STINE TARGET FAILING AND ALSO THIS IS ONE WAY.
TO COMPARE DELTA VERSION AND OMICRON VERSION. IF WE COULD TARGET PEOPLE BY STINE TARGET FAILING AND WE.
COULD SEE JUST HOW MUCH IT WAS OFF AND IT WAS OFF LESS THAN.
10%. THE OTHER THING THAT WAS NICE ABOUT THE KAISER.
PERMIANTY CLOSED SYSTEM IS WE WERE ABLE TO CLOSE FOR A.
GREAT DEAL OF DETAILS THAT WERE DIFFICULT TO CONTROL FOR, AGE, SEX,.
COMORBIDTY, PRIOR SARS INFECTION AND ALSO PRIOR.
VACCINATION AND ALSO DUE TO THE FACT THAT THIS CLOSED SYSTEM HAD EVERY ONE OF.
THOSE FEATURES, CFA WAS QUICKLY ABLE TO PERFORM AN.
ANALYSIS IN COLLABORATION WITH THE SYSTEM THAT TRULY.
WAS ABLE TO DEMONSTRATE THE COMPARISONS OF OMICRON.
VERSUS DELTA. AS WELL AS THAT DEMONSTRATED THAT THERE WAS.
LOWERED RISK OF HOSPITALIZATION, OF.
SYMPTOMMIC ATTIC ROOM HOSPITALIZATION, AGAIN,.
DELTA VARIATION IS SHOWN IN PURPLE BELOW AND OMICRON IN.
GREEN, OF INTENSIVE CARE UNIT DISCHARGE, OF MECHANICAL.
VENTILATION AND OF DEATH.
SO GIVEN THAT WE.
WERE ABLE TO CONTROL FOR ALL OF THOSE HARD-TO-CONTROL FOR.
ATTRIBUTES THAT WE COULD DISTINGUISH OMICRON FROM.
DELTA, AS WELL AS THAT WE HAD A SHUT SYSTEM, WE WERE.
FEELING BETTER THAT WE WERE NOT GOING TO SEE EVEN MORE.
EXTENT CASE FOR SITUATION IN OMICRON. NEVERTHELESS, WE ALSO.
RECOGNIZE THAT GIVEN THE VOLUME OF THE VARIETY OF.
CASES, WE VERY WELL MAY HAVE CHALLENGES FROM A HEALTHCARE FACILITY.
CAPABILITY VIEWPOINT. I REVEAL THIS. THIS IS ALSO A SLIDE.
FROM THAT RESEARCH THAT IS CURRENTLY PUBLISHED, I COUNT ON.
NATURE MEDICATION THAT HAS SHOWN THE CLINICAL.
OUTCOMES BY HEALTH CENTER LENGTH OF REMAIN. SO THE AVERAGE.
SIZE OF STAY, EVEN FOR DELTA WAS ABOUT SIX DAYS.
VERSUS 2 DAYS FOR OMICRON.30% OF DELTA.
HOSPITAL STAYS WERE LESS THAN 2 DAYS. ABOUT 85% OF.
THE OMICRON HOSPITALIZATIONS WERE LESS THAN TWO DAYS. SO.
ONCE MORE, ANOTHER AMONG THOSE QUESTIONS THAT YOU HAVE A.
NEW VARIANT. HOW ARE WE GOING TO TELL WHETHER IT'' S. EVEN MORE SEVERE? AND WE WERE DOING THE EVALUATIONS TO.
UNDERSTAND WHETHER IT WAS MORE SEVERE. THE NEXT.
QUESTION, OBVIOUSLY, IS HOW WELL DO OUR VACCINES WORK? THIS HAS BEEN– WE HAVE A MASSIVE SPREADSHEET OF OUR.
VACCINATION EFFECTIVENESS RESEARCHES AS WELL AS SYSTEMS, BUT.
ALLOW ME TO PROVIDE YOU A FEELING OF ALL OF THESE RESEARCHES AS WELL AS.
PLATFORMS THAT WE HAVE.
SO WE HAVE THE COVID WEB.
RESEARCH STUDIES. NOS HE ARE HOSPITALIZED CLIENTS, ALL.
AGES AND YOU TIN SEE THE DISTRIBUTION THROUGHOUT THE.
UNITED STATES. WE HAVE THE IVY RESEARCH, HOSPITALIZED.
INDIVIDUALS AMONGST THOSE 18 AND ALSO OLDER. WE HAVE THE VISION.
SYSTEM, WHICH IS ED, URGENT TREATMENT, AND.
HOSPITAL STAYS ACROSS ANY AGE. ONCE MORE, VARIOUS.
WEBSITES. THE HEROES-RECOVER STUDY IS.
A HEALTHCARE WORKER RESEARCH. THESE ARE FRONTLINE EMPLOYEES,.
AND ALSO THEY TAKE PART IN ASYMPTOMATIC SCREENING,.
ONCE AGAIN, IN NUMEROUS AREAS THROUGHOUT THE UNITED STATES AND ALSO.
FINALLY, THE CONQUERING COVID-19 SYSTEM.
THESE.
ARE HOSPITALIZED PEOPLE AND ALSO YOUNGSTERS, NONETHELESS. IT.
IS A COMBINATION OF THESE OPERATING SYSTEMS. NOT ANY SINGULAR.
ONE THAT ASSISTS OFFER US AN UNDERSTANDING OF HOW THESE.
VACCINE WORKING. AS SOON AS WE HAD OMICRON, WE HAD THE.
QUESTION, HOW WELL WILL OUR VACCINES WORK? THESE WERE.
SOME OUR FIRST INFORMATION LOOKING AT INJECTION EFFECTIVENESS.
VERSUS ED VISITS AND URGENT TREATMENT SEES. THAT WERE.
APPEARING OF DELTA, AND ALSO THIS WAS, ONCE MORE, THROUGHOUT THE.
DELTA PERIOD, THIS WAS OUR VISION VISION SYSTEM AND.
WE COULD SEE THE INJECTION EFFECTIVENESS, LESS THAN SIX.
MONTHS AFTER DOSE TWO, EARLY DAYS, WAS ABOUT 86%. MORE THAN SIX MONTHS, WE SAW SOME WANING, TO.
76%. AFTER THE 3RD DOSE THIS WAS SORT OF INSPIRATION.
FOR THE BOOSTER DOSE, WE SAW A BOLSTERING OF THAT VACCINE.
EFFECTIVENESS VERSUS ED VISITS AND URGENT CARE.
GOS TO, AS MUCH AS 94%.
BELOW THEN IS THE DATA THAT.
ARISED AFTER OMICRON. WE SAW OMICRON HAD LESS– THAT.
EVERYTHING WAS LESS. SO ESSENTIALLY, WE SAW THAT IF.
YOU ONLY HAD TWO DOSAGES AND ALSO EVEN IF YOU WERE LESS THAN.
SIX MONTHS OUT, YOUR VE AGAINST OMICRON WAS ABOUT.
52%. ABOVE 6 MONTHS, IT WOUND DOWN MORE, DOWN.
TO 38% AND AFTERWARDS THIRD DOSE, YOU IN FACT GOT A.
ROBUST REBOUND OF YOUR VACCINE PERFORMANCES, AS MUCH AS.
82% AND ALSO THIS WAS REALLY VITAL INFO TO.
SAY, YES, IN AN ERA OF OMICRON, IT IS REALLY.
ESSENTIAL TO OBTAIN THAT BOOSTER DOSAGE. CURRENTLY THIS IS.
VE AGAINST EMERGENCY DEPARTMENTS AND URGENT TREATMENT.
CENTERS. EVERYTHING WENT UP AGAIN, VE WHEN CONSIDERING.
HOSPITALIZATIONS. IT EXECUTE BETTER AGAINST.
DELTA. IT CARRIES OUT A LITTLE LITTLE BIT BETTER AGAINST OMICRON. YOU SEE THAT WANING AFTER THE 2ND DOSAGE, TO 57%.
AND ONCE AGAIN, INFORMATION HERE, AFTERWARDS THIRD DOSAGE WITH.
OMICRON, YOU CAN OBTAIN UP TO 90% SECURITY AGAINST.
HOSPITALIZATION KEEPING THAT THIRD DOSAGE.
YOU RECOGNIZE, SOME.
OF DENOMINATOR INFORMATION HAS BEEN DIFFICULT TO COMPREHEND AND ALSO HARD.
TO COVER OUR HEAD AROUND. I THINK THAT THIS IS ACTUALLY.
AN IMPORTANT– OOPS, AN IMPORTANT SLIDE TO COMMUNICATE.
WHICH IS, HOW ARE WE PERFORMING WITH OUR.
HOSPITALIZATIONS, WITH OUR THIRD BOOSTER DOSAGE? THIS IS.
CURRENTLY DECEMBER OF 2021. WHAT WE COULD SAY IS AMONG THOSE.
OVER THE AGE OF 65, INDIVIDUALS OVER THE AGE OF 65 THAT WERE.
UNVACCINATED REPRESENTED 12% OF THE POPULATION, BUT 54%.
OF INDIVIDUALS THAT WERE IN THE HEALTHCARE FACILITY. SIMILARLY, PEOPLE.
WHO WERE BOOSTED AS WELL AS OVER THE AGE OF 65, STOOD FOR.
57% OF THE BASIC POPULACE AND ALSO ONLY 8% OF.
PEOPLE THAT ARE HOSPITALIZED. SO THIS SLIDE BOTH.
RECOGNIZES THAT THERE ARE PEOPLE THAT ARE GOING TO BE.
OVER THE AGE OF 65 THAT ARE BOOSTED AND ALSO ARE GOING TO GET.
HOSPITALIZED. THOSE 8%. BUT THEY'' RE DISPROPORTIONAL.
TO THE FRACTION OF INDIVIDUALS IN THE POPULATION.
THAT WAS.
REALLY WHAT WE WERE TRYING TO SHARE. SO AMONG THE.
POINTS THAT HAD BEEN SO CHALLENGING AND ALSO ONE OF THE.
LESSONS THAT I HAVE FOUND OUT IS THAT POLICY AND ALSO ACTIVITY DO.
NOT SPARE THE HOLIDAYS. SO LITERALLY, WE WENT FROM.
THANKSGIVING TO CHRISTMAS AS WELL AS IN REALLY A THREE TO.
FOUR-WEEK PERIOD OF TIME AS WELL AS WE WERE SEEING THIS MASSIVE.
SCALE-UP OF CIRCUMSTANCES WE YES PREPARING FOR A RAPID.
SUBSTANTIAL SURGE IN SITUATIONS, RELATIVELY LOWER.
HOSPITALIZATIONS, BUT A LARGE, ABSOLUTE VARIETY OF.
HOSPITAL STAYS. WE WERE EXPECTING OMICRON.
TRANSMISSION TO BE HIGHER, THAT IT MAY ESCAPE RESISTANCE.
WHEN IT COME TO INFECTION WHICH OUR VE AGAINST.
INFECTION WAS PROBABLY GOING TO BE DOWN.
WE ALSO.
UNDERSTOOD THAT FOR ALL OTHER VARIANTS ANYWAY, AS WELL AS.
WE DIDN'' T HAVE DEFINITIVE DATA FROM THE OMICRON.
ALTERNATIVE, HOWEVER, FOR ALL OTHER VARIANTS, A LOT OF SARS-COV-2.
WERE HAPPENING 1 TO 2 DAYS BEFORE SYSTEMS AND 2 TO.
THREE DAYS AFTER SIGNS AND SYMPTOMS. WE DIDN'' T THINK OMICRON.
WOULD BE DIFFERENT BUT WISHED TO ACKNOWLEDGE THAT.
WE DIDN'' T HAVE FULL LINE OF VISION OF THAT. AS WE WERE.
LOOKING AT DURATION OF INFECTIOUSNESS AND ALSO WE WERE.
REQUIRING TO UNDERSTAND AND DEVELOP POSSIBLY NEW.
POLICY AROUND ISOLATION AND QUARANTINE AS WELL AS WE'' LL TALK.
ABOUT THAT SOON. WE WERE LOOKING AT THIS PERIOD.
OF INFECTIOUSNESS. IF YOU COULD FLAWLESSLY ISOLATE WHEN.
YOUR SIGNS AND SYMPTOM BEGINNING IS AND PHONE CALL IT DAY NO, THE PERIOD.
OF INFECTIOUSNESS WAS DAY MINUS 2 TO DAY SEVEN OR.
SO, THAT WE KNEW THAT PCRs AND VIRAL TONS HAD A TAIL,.
THAT ALL OF THOSE VIRAL TONS IN THAT TAIL WERE.
PROBABLY NOT INFECTIOUS.
WE WERE GRABBING SOME VIRAL.
PARTICLES. WE ALSO KNEW THAT PEOPLE WERE TESTING AT.
VARIOUS TIMES. AS WELL AS THAT IF YOU KIND OF SPECIFY YOUR.
SIGNS AND SYMPTOMS AND SPECIFY YOUR TEST AS, WELL, I TESTED A.
DAY OR 2 AFTER MY SYMPTOMS STARTED OR I TESTED THE.
EXACT SAME DAY THAT MY MANIFESTATION BEGAN THAT YOU.
HAD SOME ACTUALLY FLUIDNESS IN THAT DAY NOS OF A.
POSITIVE TEST. WE HAD TO ACKNOWLEDGE THAT, WHICH.
PROBABLY THE MAJORITY OF INFECTIOUSNESS OCCURRED BEFORE COMPLETION OF.
DAY FIVE, ACKNOWLEDGING LIKEWISE THAT NOT ALL INFECTIOUSNESS.
TAKEN PLACE PRIOR TO DAY FIVE WAS OVER.BUT THERE WAS– WE
HAD TO ACKNOWLEDGE THERE IS LIKE THIS UNCERTAINTY THAT
IS HAPPENING IN THIS PERIOD, WHICH PROBABLY ENCOMPASSES
THIS DURATION TOO.
BUT THINGS THAT WAS HAPPENING
THAT WAS REALLY A DIFFICULTY AT THE TIME WAS WHAT WAS
GOING ON IN THE REAL WORLD, AND ALSO I WOULD WONDER TO
HOW YOU AND ALSO YOUR HOSPITAL SYSTEM FELT THE IMPACT OF
THIS. I WAS LISTENING TO AS I WAS CANVASSING COWORKERS
THROUGHOUT THE NATION THAT DRUG STORES COULDN'' T DISPENSE INSULIN BECAUSE THEY HAD WAY TOO MANY PHARMACISTS THAT WERE OUT. THEY NEEDED TO SHUT THE PHARMACY COUNTERS. I HEARD BLOOD SOCIETY BOTTLES WERE NOT REACHING SIGNIFICANT MEDICAL FACILITY DUE TO TRANSPORT BECAUSE TOO MUCH OF TRANSPORT WAS OUT. I LISTENED TO THAT DIALSATE WAS NOT REACHING DIALYSIS FACILITY BECAUSE FED EX-SPOUSE WAS OUT. WE WERE SEEING A CRUMBLE OF COMMERCIAL AS WELL AS SECTOR, WE WERE SEEING A CRUMBLE OF HOSPITALS, HEALTH TREATMENT DISTRIBUTIONS AS WELL AS HEALTH AND WELLNESS TREATMENT FACILITIES STRUGGLING WITH STAFFING SHORTAGES IN ALL AREAS SINCE NUMEROUS PEOPLE WERE NOW BECOMING SYMPTOMATIC WITH OMICRON, WHICH WE REALLY DID NEED TO FIND OUT HOW WE WERE GOING TO ADJUST OUR POLICIES FOR THE MINUTE. WE WERE ALSO STARTING TO SEE THAT DECOUPLING OF WHAT WE SAW IN GUETANG DISTRICT IN AFRICA. WE SAW SITUATIONS SKYROCKETING AND ALSO HOSPITALIZES GOING UP AND ALSO DEATHS INCREASING BUT NOT AT THE RATE OUR INSTANCES WERE GOING UP. THE REASON THIS SLIDE IS POTENT IS YOU CONTAINER REALLY SEE THE DECOUPLING, BUT YOU CAN SEE THE HEALTHCARE FACILITY ADMISSIONS IN JANUARY OF 20E 22 WAS ALREADY GREATER THAN IT WAS FOR OUR DELTA WAVE IN THE SUMMER SEASON.
YOU ACTUALLY SEE THIS NICE DECOUPLING BUT HOW THIS MASSIVE NUMBER OF CASES WAS GOING TO CAUSE CHALLENGES IN BOTH HOSPITALS, HOSPITALIZATIONS AND A RISE IN THE VARIETY OF DEATHS. SO WE FELT THAT IT WAS VERY IMPORTANT TO BE APPROPRIATE TO THE MOMENT AND TO SAY THAT WE NEEDED TO MODIFICATION OUR ISOLATION AND QUARANTINE ADVICE TO A DAMAGE DECREASE SITUATION, WHERE WE NEEDED PEOPLE TO ISOLATE DURING THE TIME PERIOD WHERE THEY WERE A LOT OF INFECTIOUS AS WELL AS THEN TO POTENTIALLY LEAVE ISOLATION AND ALSO WEAR A MASK FOR THAT FINAL FIVE DAYS WHEN THEY WERE LIKELY POSSIBLY MIGHT HAVE SOME HARBORING INFECTION, LIKELY MUCH LESS THAN THE MINUS DAY TWO TO DAY 3.
BUT IF THEY REQUIRED TO, THEY COULD LEAVE ISOLATION. WE SIMILARLY HAD– BECAUSE SO LOTS INDIVIDUALS WERE NEEDING TO QUARANTINE, WE INTENDED TO MAKE CERTAIN THAT INDIVIDUALS WERE QUARANTINING DURING THE A LOT OF AT-RISK AMOUNT OF TIME, FIVE DAYS AFTER EXPOSURE, AS OPPOSED TO HAVING PEOPLE OUT FOR 14 DAYS WHEN THEY WERE LIKELY AT LESS THREAT AFTERWARDS FIVE DAYS BUT AGAIN, WEARING A MASK TO ALLEVIATE THAT THREAT. THAT WAS THE INSPIRATION REALLY FOR THE CHANGE AND ALSO THE GUIDANCE AT THE TIME, AND ALSO ULTIMATELY, YOU CAN SEE WHAT OCCURRED DURING OUR OMICRON WAVE RIGHT HERE, THE DECOUPLING OF OUR CASES, OUR HEALTH CENTER ADMISSIONS AS WELL AS FATALITIES, AS WELL AS ULTIMATELY, YOU SEE ALSO DURING THE OMICRON WAVE, OUR HOSPITALIZATIONS PEAKED GREATER THAN OUR DELTA WAVE IN ADDITION TO DURING OUR ALPHA WAVE. NOW AMONG THE THINGS THAT THIS ALSO PLED THE CONCERN OF IS, ARE WE DETERMINING THE RIGHT THINGS? AS WE CONSIDER MOVING ONWARD.
WHAT MUST BE THE PLAN SINCE WE HAVE SUCH AN INFECTIOUS VARIANT? ALSO THAT WE KNOW THAT WE MAY HAVE MUCH MORE INFECTIONS THAN WE ARE CAPTURING SPECIFICALLY AS WE ARE SCREENING AN INCREASING NUMBER OF UTILIZING ANTIGEN TESTING. WE WERE INSPIRED TO REFOCUS NOT JUST ON TRANSMISSION, BUT ON COMMUNITY WORRY. WE ACKNOWLEDGED THAT THERE WAS A CURRENT DEGREE OF HIGH POPULATION IMMUNITY. THIS IS NOW DIALING US BACK TO REGARDING FEBRUARY OR MARCH OF 2022. THERE WAS HIGH POPULACE RESISTANCE. LOTS OF PEOPLE HAD BEEN VACCINATED. MANY INDIVIDUAL HAD PRICE STEM INFECTIONS AND MANY INDIVIDUAL HAD PRIOR PROTECTION FROM BOOSTING AS WELL AS AND WE HAD EVOLUTION OF SCREENING STRATEGIES INCLUDING AT-HOME AS WELL AS POINT-OF-CARE EXAMINATIONS AND ALSO THIS WAS AS OUR MMWR WAS APPEARING THAT I HIGHLIGHTED EARLIER, AS WELL AS THAT OUR FOCUS SHOULDN'' T NECESSARILY GET ON THE NUMBER OF CASES WE HAVE, BUT ON MINIMIZING COVID-19 INFLUENCE ON WELLNESS AS WELL AS CULTURE.
WHAT WE REALLY DESIRED TO MAKE CERTAIN IS THAT WE WERE STOPPING CLINICALLY CONSIDERABLE AILMENT, THAT WE WERE MINIMIZING THE WORRY ON THE HEALTH CARE SYSTEM, THAT OUR HEALTH TREATMENT SYSTEM COULD BE FUNCTIONAL AND ALSO THAT WE WERE SECURING ONE OF THE MOST VULNERABLE. SO PREVIOUSLY YOU MAY RECALL, WE HAD A.
TRANSMISSION PARAMETER. WE HAD TRANSMISSION INDICATORS.
THAT WERE INFORMING ALL OF OUR PUBLIC WELLNESS ASSISTANCE,.
INCLUDING OUR COLLEGE OPENING SUPPORT, OUR CONGREGANT.
SETTING ASSISTANCES AND LOTS OTHER ASSISTANCES WHERE THE.
OBJECTIVE AT THE TIME WAS TO LIMITATION TRANSMISSION, NOT TO.
PREVENT EXTREME ILLNESS. OBVIOUSLY, WE WOULD LOVE TO.
RESTRICTION TRANSMISSION TOO. BUT THIS NEITHER REFLECTED.
HEALTH AND WELLNESS CARE BURDEN OR CLINICALLY CONSIDERABLE.
DISEASE. IT WAS MAINLY DRIVEN BY BY AN ABSOLUTE.
VARIETY OF CASES WITHOUT A DAIMPTIONATION OF THOSE LIGHT.
TO EXTREME SITUATIONS LIKEWISE WITHOUT A RECOGNITION THAT WE WERE.
NO MORE CAPTURING ALL THOSE SITUATIONS WELL SINCE SO.
MUCH WAS HAPPENING IN ANTIGEN SCREENING. AS WELL AS SO.
WHAT WE CHOSE TO PIVOT FOR, WHAT WE DID OPT TO PIVOT TO.
WAS CAPTURING COVID-19 AREA LEVELS. WE DESIRED.
TO CERTAINLY HAVE CASES INFORMED AND YOU CAN SEE ON.
THE LEFT-HAND BORDER, FEWER THAN 200 PER 100,000 BUT.
ALSO– YEAH.
200 PER 100,000 IN THE LAST 7 DAYS.
BUT ALSO HAVE IT INFORMED BY NEW ADMISSIONS PER 100,000,.
BY STAFFED IN-PATIENT BEDS INHABITED BY COVID-19.
INDIVIDUALS. AND ALSO AMONGST THE IMPORTANT THINGS AS WE WERE THINKING.
REGARDING WHAT ARE THE MOST IMPORTANT CRITERIA TO.
NOTIFY THESE COVID-19 NEIGHBORHOOD LEVELS FROM A.
PLAN LEVEL, WHEN MUST WE BE REALLY WORRIED BECAUSE.
ORANGE DEGREE? WHEN OUR HOSPITALS ARE FULL, WHEN OUR.
BEDS ARE OCCUPIED WITH COVID PATIENTS? WE REALLY LOOKED.
AT SEVERAL STANDARDS. WE WANTED– FIRST OFF, GIVEN.
THAT THIS WAS GOING TO BE NATIONAL POLICY, WE NEEDED.
INFORMATION THAT WERE AVAILABLE AT THE AREA DEGREE OR.
ALLOCATED TO THE AREA DEGREE TO EDUCATE WELLNESS.
SOLUTION LOCATION. THIS WAS REALLY IMPORTANT. INDIVIDUALS.
ASKED WHY WE DIDN'' T USE WASTE WATER HERE.
AMONG. THE REASONS IS BECAUSE WE DIDN ' T HAVE DRAINAGE. REPRESENTATION FROM EVERY ONE OF OUR JURISDICTIONS. WE.
REQUIRED DATA THAT REFLECTED MEDICALLY SUBSTANTIAL.
DISEASE AND ALSO HEALTHCARE WORRY AND ALSO WE NEEDED DATA.
THAT WERE REPORTED AT THE VERY LEAST WEEKLY SO WE COULD HAVE A.
TIMELY UPDATE TO NOTIFY OUR DECISIONS IN REAL TIME.
WE.
DID CONSIDER SEVERAL OTHER INDICATORS AS I JUST.
STATED. NATIONAL SYNDROMIC SECURITY WOULD.
HAVE BEEN An EXCELLENT ONE. THIS REPRESENTS 71% OF OUR.
EMERGENCY SITUATION LEAVE MANIES OF THE WE ARE FUNCTIONING TO SCALE.
THAT UP BECAUSE IT'' S SO KEENLY IMPORTANT. AT THE.
TIME, WE DIDN'' T– WE STILL DON ' T HAVE NATIONAL.
SYNDROMIC MONITORING FOR EVERY ONE OF OUR EMERGENCY DEPART.
MANIMENTS. DRAINAGE, BUT AT THE TIME, WE HAD 600.
SITES AS WELL AS IT EXCLUDED COMMUNITIES ON SEPTIC.
SYSTEMS AND ALSO OMITTED THE ENTIRE STATE OF ALASKA, FOR.
INSTANCE. FATALITY PRICES. CERTAINLY FATALITY FEES.
CLEARLY AN IMPORTANT BAROMETER FOR US TO ACTION. IT WAS A LAGGING INDICATION WHEN IT'' S A RARE OCCASION IN A. JURISDICTION. IN SOME CASES THOSE INFORMATION ARE DELAYED. IN SOME CASES THOSE INFORMATION ARE UNPREDICTABLE AT THE COUNTY.
DEGREE. THAT WAS AMONGST THE FACTORS WE DIDN'' T PICK THIS
. SIGN. I HAVE PROVIDED NUMEROUS PRESENTATIONS LIKE.
THIS, PRESENTING THIS MAP. THIS IS AMONG THE NICEST.
IT'' S EVER LOOKED. WE STILL ARE WATCHING AREAS IN THE. NORTHEAST, FOR INSTANCE.
WE ENJOYED NOT JUST THE. STAGNANT MAP BUT CERTAINLY, THE PERCENT CHANGE IN THE.
FADS.
YOU TIN SEE WE HAD REGARDING 2% OF OUR COUNTIES NOW.
THAT GO TO HIGH. REGARDING 18% THAT ARE TOOL AND ALSO ABOUT.
80% THAT ARE LOW AND ALSO ON OUR WEBSITE, WE HAVE NOT ONLY.
RECOMMENDATIONS FOR TERRITORIES, LIKE IF YOU.
REMAIN IN A HIGH REGION, WE DO RECOMMEND THOSE.
JURISDICTIONS CARRY OUT CONCEALING POLICIES BUT ALSO.
RECOMMENDATIONS OF AN PRIVATE DEGREE. IF YOU.
ARE RESIDING IN An AREA THAT IS HIGH, YOU MAY INTEND TO PUT.
ON YOUR MASK AT THAT DURATION OF TIME. IF YOU'' RE IMMUNO. COMPROMISED AND ALSO LIVING IN A REGION THAT'' S TOOL, YOU.
MAY WISH TO PUT ON YOUR MASK. YOU MAY WISH TO USAGE.
ANTIGEN TESTS MORE LIBERALLY OR HAVE SITE VISITORS MAKE USE OF THOSE.
ANTIGEN EXAMINATIONS EVEN MORE LIBERALLY. I DO WISH TO SAY.
THAT ON OUR WEB SITE KEEP AN TRACK OF THE COVID-19 LEVELS.
AND THESE ARE THE AREA TRANSMISSION. I'' M SORRY,.
COVID-19 NEIGHBORHOOD TRANSMISSION. THESE ARE THE.
LEVELS WE'' RE ASKING OUR HEALTH AND WELLNESS TREATMENT EMPLOYEES AS WELL AS.
HEALTH AND WELLNESS CARE FACILITIES TO CONSIDER IN REQUISITES OF THEIR.
CONCEALING PLANS, ACKNOWLEDGING THAT WE DO REQUIREMENT.
A HIGHER BAR BECAUSE TRANSMISSION IN– LACK OF.
TRANSMISSION IN OUR HEALTHCARE FACILITIES IS SO VERY.
IMPORTANT THEREFORE WE STILL, ON OUR WEB SITE, HAVE BOTH OF.
THESE MAPS THAT WE KEEP ACTIVE CONSTANTLY.
IN THE.
BIG PICTURE, THE STRUCTURE FOR CHECKING AND.
PREVENTION WAS THIS MIDDLE PIECE, WHICH IS THE COVID-19.
NEIGHBORHOOD DEGREES WHICH REALLY SHOULD, AT LEAST IN.
OUR MIND, INFORM PREVENTION MEASURES, LIKE MASKING, LIKE.
TESTING, LIKE COMMUNITY LEVEL APPROACHES. WE ALSO.
IDENTIFY THAT COVID-19 INJECTION COVERAGE, IN THIS.
UPPER, LEFT-HAND CORNER, IS REALLY IMPORTANT. RETAINING.
INDIVIDUALS APPROXIMATELY DATE, ACQUIRING THEIR VALENT INJECTION. AND ALSO.
THAT WILL AFFECT HOW FULL YOUR HEALTH CENTERS ARE AS WELL AS HOW.
MANY CASES YOU HAVE. THINGS WILL BE INFLUENCED AT THE.
NEIGHBORHOOD LEVEL. WILL THERE BE INFORMATION FROM DRAINAGE.
SURVEILLANCE? HOW ARE WE DOING FROM A HEALTH AND WELLNESS EQUITY.
PERSPECTIVE? EXISTS A MAJOR CONVENTION CONVENING.
IN THAT JURISDICTION? ALL THE OF THIS UPCOMING WITH EACH OTHER.
OUGHT TO AID INFORM CITIZEN VACCINE OUTREACH AND.
DISTRIBUTION, PREVENTION ACTIONS, ALONG WITH LOCAL.
POLICY DECISIONS.
I WILL CERTAINLY ADDITIONALLY KEEP IN MIND THAT WE HAVE SINCE.
UPGRADED OUR COVID-19 SECLUSION AND QUARANTINE.
POLICIES. YET AGAIN, RECOGNIZING THAT OUR VACCINE.
EFFICIENCY IS NOT WORKING TOO NECESSARILY AGAINST.
INFECTION AS IT HAD, AGAINST– AGAINST URGENT.
TREATMENT VISITS AND ALSO HOSPITALIZATIONS. IT'' S STILL FUNCTIONING WELL BUT LESS WELL.
WE ALSO. ACKNOWLEDGE THE IMPROVED USE ANTIGEN TESTS AND HOW.
MANY INDIVIDUALS WANT UTILIZING THOSE ANTIGEN TESTS.
TO LEAVE SECLUSION, WHICH LOTS OF PEOPLE NOW NUMEROUS.
PEOPLE ESPECIALLY UNTIL SCHOOLS, ESPECIALLY IN OTHER.
AREAS ARE EXPOSED TO– POSSIBLY SUBJECTED TO.
OMICRON, TO FLOWING VERSIONS WHICH WE ARE.
ASKING PEOPLE RATHER OF STAYING RESIDENCE TO QUARANTINE.
TO MASK FOR 10 DAYS.
WHAT I ASSUMED I WOULD DO NOW IS.
TO INFORM YOU WHERE WE REMAIN IN THE CURRENT PHASE AND ALSO.
KEEPING TRACK OF VARIANTS AND ALSO FOR THOSE OF YOU THAT FEELING LIKE.
IT'' S ALPHABET SOUP AROUND, WELL, THERE'' S A GREAT. REASON FOR IT. THAT IS BECAUSE THIS IS WHAT ONE. PICTURE OF WHAT OUR VARIANT MAPPING LOOKS LIKE RIGHT NOW.
P THERE ARE A GREAT DEAL OF SUB-OMICRON VARIATIONS THAT.
ARE EMERGING AND ALSO CONVERTING ACTUALLY IN STIPULATIONS OF.
DEVELOPMENT. WHAT'' S VARIOUS IN THIS MINUTE IS NEARLY ALL. OF THESE ARE SUB-VARIANTS OF OMICRON ITSELF. WE SAW.
MASSIVE WAVES AFTER ALPHA. WE SAW ONE WITH DELTA. THOSE ARE NEW VARIATIONS AND THESE ARE ALL SINGLE.
ANOMALIES, SEVERAL MUTATIONS THAT ARE BRANCHING OFF FROM.
EITHER BACHELOR’S DEGREE.2, BA.4 OR BACHELOR’S DEGREE.5.
WE'' RE VIEWING THESE. MUTATIONS THOROUGHLY. YOU CAN SEE SEVERAL APPEAR.
REGULARLY. R346T. YOU SEE IT NUMEROUS PATHWAYS, THIS.
CONVERTING ADVANCEMENT. ONE OF THE REASONS THAT WE ARE.
WORRIED ABOUT THAT 346T IS DUE TO ITS RESISTANCE TO.
L-SHOT AND ALSO YOU SEE THAT IN NUMEROUS PATHWAYS AND ALSO IT'' S. INTERESTING TO SEE WHERE THESE ADHERES TO OR BRANCH OFF. WE HAVE A BIVAL ANT VACCINE THAT TARGETS THE WILD TYPE.
AND ALSO BA.4 AS WELL AS BACHELOR’S DEGREE.5, AND ALSO WE ANTICIPATE MORE RESISTANCE FROM.
THE BA.4, BA.5 LINEAGE AS WELL AS KEEPING THAT, I WILL CERTAINLY REVEAL YOU.
THAT THIS IS IN WHICH OUR VARIANT MAP RESEMBLES RIGHT.
CURRENTLY, BA.5 IS ALL OF THOSE BIG, TALL ECO-FRIENDLY PUBS AS WELL AS.
WE'' RE VIEWING VERY VERY CAREFULLY BQ1 AND ALSO BQ11. BQ1. IS WITH THE LITTLE ICON THERE.
THAT ' S BECAUSE WE. ARE FOLLOWING THOSE CAREFULLY AS WELL AS THOSE ARE OUR. GREATEST ISSUE NOW.
BOTH FOR THE VARIETY OF. MUTATIONS BUT ALSO FOR THE INFLUENCE AND THE FIENDNO KIND. THAT WE ARE CONCERNED THAT THEY MAY IMPLY.
MOST. JUST RECENTLY AND THESE COME OUT EVERY WEEK ON THURSDAY, WE.
ARE NOW CASTING ABOUT BQ.1 BEING 9.4%. BQ.1.1 AT 7.2%. EARLY WITH REASONABLY HANDFUL OF SEQUENCES. WE HAVE LARGER CONFIDENCE IN OUR GOALS SIMPLY TO BE AWARE.
OF. THE DOUBLING TIME OF THESE FOR BOTH VARIANTS.
COMPARED TO BA.4 AND BA4.6 AND BACHELOR’S DEGREE.5 HAS ACTUALLY RAISED. TIME FOR BQ.1 IS 10 DAYS FOR BQ.1.1 ABOUT SIX DAYS AS WELL AS.
BOTH VERSIONS ARE EXPECTED TO HAVE EVUSHELD AND ALSO.
BEBTELOVIMAB RESISTANCE. THERE ARE NO CURRENT DATA TO.
SUGGEST REDUCED INJECTION EFFICIENCY BUT SOMETHING.
WE ARE WATCHING, NATURALLY, EXTREMELY CAREFULLY. IF WE LOOK.
AT THIS BY AREA, WE ALSO MAP OUR VARIANTS BY REGION. YOU CAN SEE IT AS VARIOUS THROUGHOUT THE MAP.
IN AREA.
2, YOU CAN SEE THAT FIFTY PERCENT OF OUR VARIANTS ARE NOW.
PREDICTED TO POSSIBLE OR HALF OF OUR SEQUENCES ARE.
ANTICIPATED TO POSSIBLY HAVE EVUSHELD RESISTANCE IN.
AREA 3, YOU ARE CLOSE TO 60% IN YOUR REGION. REGION.
10, ONLY 25%. SO AGAIN, SOMETHING WE CONCENTRATE ON.
VERY CAREFULLY AND ONE OF THE FACTORS TO DO THIS IS TO.
SORT OF SAY, WE STILL HAVE 350 TO 400 DEATHS EVERY.
SINGLE DAY. THESE ARE DATA ARE UP ON OUR CDC WEB SITE. WITH REFERRAL TO THE 18 TO 29-YEAR-OLDS AND ALSO WHEN WE.
TAKE A LOOK AT DEATHS BY AGE, WE SEE 340 FOLD RISE FOR.
THOSE OVER 65. 140 FOLD FOR THOSE OVER THE AGE OF 75. ALSO AMONGST THOSE 40 TO 49, 10-FOLD THREAT OF DEATH. SO.
THIS IS THE FUNCTION THAT WE HAVE AHEAD OF United States. WHEN WE.
SPEAK ABOUT WHERE WE ARE WITH BOOSTING, THERE WAS A GREAT DEAL OF.
WORK THAT WAS DONE NUMEROUS MONTHS AGO IN THE SPRINGTIME AND.
EARLY SUMMERTIME SPEAKING ABOUT THE RELEVANCE OF GETTING A.
FOURTH DOSAGE, ESPECIALLY FOR THOSE WHO ARE IMMUNO.
REDUCED, THOSE WHO WERE ELDERLY. THESE ARE DATA OUT.
OF ISRAEL IN WHICH YOU HAVE TIMES THAT YOU OBTAINED YOUR.
4TH DOSAGE CONTRASTED TO THE 3RD DOSE. WELL, I SHOULD.
STATE THE Y-AXIS IS THE ADJUSTED PROBABILITIES RATIO CONTRASTED.
TO THE THIRD DOSE AS WELL AS THE DOTS REPRESENT VE AGAINST.
INFECTION IN BLUE AND ALSO AGAINST SEVERE CONDITION IN.
ORANGE.
CERTAINLY THE CONFIDENCE PERIODS ARE.
WIDE FOR SERIOUS DECEASE. NOW, WE HAVE.
REASONABLY RARE OUTCOMES. YOU CAN SEE A SHORT-TERM BUMP.
IN HOW IT CANISTER AID YOU AGAINST INFECTION EARLY ON.
AS WELL AS MAYBE AID YOU FOR SOME AMOUNT OF TIME. BUT THE.
REAL BENEFIT OF THAT FOURTH DOSE WAS, AGAIN, SEVERE.
ILLNESS, ESPECIALLY FOR THAT ELDERLY POPULACE. HERE IS.
CURRENTLY HOW WE'' RE REALLY LOOKING AT VE ACROSS NUMEROUS OF OUR.
SYSTEMS, BUT THIS IS– THIS IS A IMMUNO COMPETENT.
GRAPH. BEAR WITH ME. ALL-TIME LOW REVEALS VERSUS BA.4.
AND BA.5. YOU SEE TWO DOSES OF INJECTION SHOWN IN ENVIRONMENT-FRIENDLY. 3 DOSES IN BLUE AND ALSO FOUR DOSAGES DISPLAYED IN BLACK. AND.
AFTER THAT WHAT YOU TIN SEE MOVING DOWN THE TOP BOX, OR DOWN.
THE BOTTOM BOX, IS WHAT HAPPENS WITH BOOSTED TIME.
DELICATE VACCINATION. YOU CAN SEE WITH YOUR TIME DOSED.
AND ALSO THIS IS URGENT CARE CHECKS OUT, AROUND 50%, WHICH.
WANED WITH TIME. WITH THE 3RD DOSAGE, YOU OBTAINED MUCH OF.
THAT VE BACK.
ONCE AGAIN, WOUND DOWN OVER TIME AND ALSO WITH THE.
FOURTH DOSE, YOU OBTAINED MUCH OF THAT VE BACK. ACTUALLY, IT.
PROBABLY INCREASED ABOVE IN WHICH IT WAS FOR SECONDLIES AND ALSO.
3RD DOSES AND ALSO COMPARABLE FADS FOR BACHELOR’S DEGREE.4 AND ALSO BA.5. WE FOLLOW THIS FOR TWO DOSES, 3 DOSES AND ALSO.
FOLLOW IT WITH TIME AND ALSO FOR EMERGENCY DIVISION SEES.
THIS IS ESSENTIALLY THE SAME GRAPH. AGAIN, FOLLOWED FOR.
HOSPITALIZATIONS. YOU SEE THAT VE WAS WANING WITH YOUR.
3RD DOSE. WE DESIRED TO BUMP IT AS MUCH AS YOUR FOURTH.
DOSAGE. VERY SIMILAR RIGHT HERE BA.4 AND ALSO BA.5. REALLY, WE.
DID DEMONSTRATE THE RELEVANCE OF THE FOURTH.
DOSAGE IN WANING IMMUNITY AS WELL AS DEFENSE AGAINST ONE OF THE MOST.
SEVERE END RESULTS IN, YOU RECOGNIZE, A HOSPITAL STAY AND.
UTILIZING THE BACHELOR’S DEGREE.4 AND ALSO BACHELOR’S DEGREE.5. WE HAVE STROVE GIVEN THE.
DIVERSIFICATION OF THE POPULATION OUT THERE, IN.
REGARDS TO WHEN THEY OBTAINED THEIR LAST DOSE, THE AMOUNT OF DOSES.
THEY HAVE RECEIVED TO REALLY STREAMLINE THE.
SUGGESTIONS. WHAT WE ANTICIPATE FOR THIS BIVALENT.
BOOST WHICH IS WITH THE WILD KIND PRESSURE, AS WELL AS IS.
THAT THE RESISTANCE IS HIGHER AND ALSO MORE SUSTAINED.
IN TIME THAN PERFORMANCE AGAINST INFECTION THAT THE.
VE WAS COMPARABLE– VE WAS COMPARABLE IN 4 AS WELL AS 5.
COMPARED TO 2 AND AFTERWARDS THE 3RD DOSAGE PROVIDED.
CONSIDERABLE PROTECTION.COVERAGE WITH THE FOURTH. DOSE HAD CONTINUED TO BE LOW AND ALSO WHAT WE ' RE REALLY WORKING TO. DO NOW IS SAY ANYBODY THAT HAS HAD AT LEAST 2 DOSES. NEED TO OBTAIN THIS BIVALENT VACCINE THIS SEASON
AND. IDEALLY WE ' RE PUSHING BEFORE HALLOWEEN.
YOU POSSIBLY. HAVE SEEN MORE PUBLIC MESSAGING GOING OUT AND I. SURE
HOPE EVERY ONE OF YOU– I EXPECT THAT ALL OF YOU ARE.
WITH United States ON THIS MESSAGE ON THE IMPORTANCE OF THIS.
BIVALENT VACCINE. SIMPLY TO PROVIDE YOU A FEELING OF WHERE
WE. ARE. WE OBTAIN THESE WEEKLY AND NOT DAILY.
WE SEE– IF. YOU CHECK OUT ANY AGE TEAMS, REGARDING 79 %OF
INDIVIDUALS HAVE. GOTTEN A MAIN SERIES.
ABOUT 49% HAD GOTTEN ONE. BOOSTER BEFORE WE TURNED OUT OUR BIVALENT CAMPAIGN AND 7%. OBTAINED A LOSS BOOSTER.
SO WE HAVE WORK TO DO. SOME. CAREFUL POSITIVE OUTLOOK BELOW IS THAT WE ARE DOING BETTER. WITH OUR HIGHER DANGER POPULACES,
THAT WE HAD. CONCERNING 93% WITH PRIMARY SERIES.
REGARDING 72% WHO HAVE. GOTTEN THE INCREASES AND ABOUT 17% WITH OUR FALL INCREASE. BUT WE DO HAVE EVEN MORE WORK TO ACCOMPLISH THERE. I DO WISH TO TALK.
A BIT ABOUT DRAINAGE BECAUSE THIS HAS BEEN.
REALLY AN IMPORTANT, NEW TOOL.
IT'' S NOT REALLY A NEW. TOOL. WE ' VE BEEN USING DRAINAGE A GREAT DEAL IN NUMEROUS.
PUBLIC HEALTH AREAS. ESPECIALLY IN POLIO, GLOBAL.
POLIO SECURITY. IT'' S GREAT SINCE IT ' S PASSIVE.
AND ANONYMOUS. IT HAS INCLUSIVE REACH. IT'' S. ACTUALLY WELL APPROVED BY THE PUBLIC. IT OFFERS.
ADAPTABILITY, TIMELY GENOMIC SEQUENCING. THERE'' S A GREAT DEAL. OF PUBLIC WELLNESS ASSISTANCE FOR IT AND REALLY, THIS TOOK A.
RISE WITH COVID-19. IN FEBRUARY OF 2022, WE HAD.
REGARDING 204 WEBSITES THAT WERE DOING WASTEWATER. WE HAVE.
984 WEBSITES WHICH HAVE THE CAPABILITY TO ACCOMPLISH WASTEWATER.
SURVEILLANCE AS WELL AS I'' M SATISFIED TO SAY THAT WE WERE ABLE TO.
TAKE ADVANTAGE OF THIS DURING THE MONKEYPOX OUTBREAK, FOR.
INSTANCE, IN WHICH WE WERE ABLE TO DETECT WASTEWATER IN 121.
NORTHERN THE GOLDEN STATE SEWER SHEDS. WE HAVE BEEN ABLE TO.
LEVERAGE IT FOR POLIO.
THIS IS A MAP OF NEW YORK CITY WITH.
INJECTION PROTECTION SEEN. BECAUSE MAP, YOU TIN SEE THE.
LIGHTEST INSURANCE COVERAGE ARE THE LOCATIONS, ROCKLAND REGION,.
WHERE WE HAD THE POLIO SITUATION AND IN WHICH WE HAVE BEEN.
PROACTIVELY WORKING AS WELL AS DOING DRAINAGE SECURITY IN.
PARTNERSHIP WITH THE STATE OF NEW YORK. I WILL KEEP IN MIND.
THAT THE RATE OF POLIO, VACCINE INSURANCE COVERAGE IN A FEW OF.
THE TERRITORIES THAT WE'' RE DETERMINING HAS TO DO WITH 67%. SO.
REALLY QUITE LOW. WASTE WATER IS NOT A CURE ALL. I.
WANT TO SAY THAT WE ARE FINDING OUT A LOT ABOUT IT. I'' M REALLY EXCITED ABOUT ITS CAPACITY FOR THE FUTURE. WE DO HAVE TO RECOGNIZE SOME OF ITS LIMITATIONS,.
DECENTRALIZED WASTEWATER SYSTEMS WILL NOT BE CAPTURED.
WE VERY WHOLE STATES AS WELL AS WHOLE TERRITORIES NOT.
RECORDED. CONCERNING 20% OF U.S. RESIDENCIES ARE NOT.
CONNECTED TO DRAINAGE. WE REALLY TO NEED TO.
UNDERSTAND HOW WE INTERPRET THE INFORMATION IN A LOW INCIDENCE.
ESTABLISHING. WHEN OCCURS IF YOU LOCATE A MICROORGANISM? IS IT.
THAT IT'' S BEEN THERE FOR WEEKS, OR DID IT JUST SHOW.
UP AND ALSO DISAPPEAR TOMORROW? DO DOWNSIDE EXAMINATIONS SHOW.
LACK OF DISEASE OR ABSENCE OF INFECTION? WE.
HAVE A LOT TO LEARN.
THIS IS PROBABLY.
PATHOGEN-SPECIFIC. WE HAVE SOME BARRIERS TO.
EXECUTION. A NUMBER OF OUR PUBLIC WELLNESS LABS ARE.
SCALING THIS UP. THERE ARE FASCINATING AND ETHICAL.
PRIVACY PROBLEMS. THERE ARE HEREDITARY DATA THAT WE CAN.
COLLECT FROM WASTEWATER AND ALSO CAPACITIES THERE THAT I.
THINK ARE REALLY INTERESTING TO DIVE DEEPER IN. I.
SUSPICIOUS THIS WILL BE AN EVER-EVOLVING, REALLY.
VITAL AREA IN TRANSMITTABLE DISEASES,.
NON-INFECTIOUS DISEASES PUBLIC HEALTH IN GENERAL. WITH THE REMAINING TIME, I BELIEVED I WOULD HIGHLIGHT.
SEVERAL OF THE THINGS THAT WE HAVE BEEN FOLLOWING IN.
MONKEYPOX.
THIS IS OUR MONKEYPOX CASE CURVE. I.
RECOGNIZE THAT WE HAD 28,000 SITUATIONS JUST IN MMWR OUT TODAY.
DESCRIBING A FEW OF THE SEVERE SITUATIONS AND ALSO DEATHS THAT.
HAVE HAPPENED. SO CERTAINLY TRAGEDIES THAT HAVE OCCURRED.
THROUGHOUT THIS AMOUNT OF TIME. THERE'' S BEEN MASSIVE
PUBLIC. HEALTH AND WELLNESS ACTIVITY, MASSIVE HEALTH TREATMENT ACTIVITY AND. HUGE PARTNERSHIP. I WISH TO THANKS ALL FOR IT,.
THAT HAS OCCURRED IN THOSE MONTHS TO BE ABLE TO BEND.
THIS CURVE AT THE SPEED THAT WE DID. WE PUT OUT 5.
HUNDREDS THOSE ARE THE RED STARS, THAT SHOWED THE FIRST.
SITUATION, FIRST TIME WAS MAY 20th. UPGRADED INSTANCE.
DISCOVERING IN JUNE. UPDATED SCREENING AND THERAPY.
ADVICE AND ALSO UPDATED THERAPY FOR TEENAGE YEARS.
AND ALSO THOSE BREASTFEEDING AS WELL AS PREGNANT.
AND ALSO.
MANIFESTATIONS CONSISTING OF THOSE WITH HIV. WE HAVE PUT.
OUT THANKS FOR CENTER OF FORECASTING AND ANALYTICS,.
TECHNOLOGICAL RECORDS REVEALED BY THESE ARROWS THAT ARE An INDICATION.
TO TYPE OF THE STATE OF THE STATE. REALLY TRYING TO OBTAIN.
OUR SCIENTIFIC RESEARCH OUT FASTER. IN THOSE TECHNOLOGICAL REPORTS, WE.
CURRENTLY HAVE UTILIZED TIME-VARYING REPRODUCTIVE NUMBERS THAT.
HAVE DEMONSTRATED THAT WE HAVE BEEN UNDER ONE FOR SOME.
PERIOD OF TIME. WE HAVE BEEN SLOWING THE DEVELOPMENT OF.
THE BREAK OUT WHICH LIKEWISE IS FANTASTIC AND A LOT OF THE.
ESTIMATES OF WHAT COULD HAPPEN IF WE DON'' T KIND OF.
MAINTAIN OUR EYE ON THE ROUND. A LOT OF THIS HAS BEEN.
ASSOCIATED. WE ACKNOWLEDGE TO EDUCATION, TO VACCINATION,.
TO ACTIONS MODIFICATION AND OF COURSE, TO SOME BOOST IN.
RESISTANCE IN THE POPULATION. WE ARE CONTINUING AND WE.
HAVE AN ACTIVE MONKEYPOX ACTION. WE CONTINUE TO FULFILL SEVERAL TIMES A WEEK AND ALSO THAT.
SCIENTIFIC RESEARCH IS CONTINUING TO PROGRESS.
PART OF THAT IS.
DUE TO OUR DATA PERTAINING TO EQUITY. YOU CAN SEE IN.
THIS CHART, WHITE POPULATION, INFECTIONS ARE.
SHOWN IN BLUE. BLACK OR AFRICAN-AMERICAN IN PURPLE. HISPANIC IN ENVIRONMENT-FRIENDLY. YOU CAN JUST VIEW AS WITH MANY.
CONTAGIOUS CONDITIONS HOW THINGS DEVELOP TO MORE RACIAL.
AND ETHNIC DIVERSE AREAS, EVEN MORE BLACK AND.
BROWN COMMUNITIES IN TIME, LIKE WITH A LOT OF MATTERS AND.
TRANSMITTABLE ILLNESS. WE HAVE A GREAT DEAL OF FUNCTION TO PERFORM.
RIGHT HERE. AMONG THE AREAS, SO IF YOU WERE TO SAY BLATANTLY,.
SIMPLY BY CONSIDERING THAT, THAT OUR POPULACE NOW IS.
TO ABOUT A THIRD AFRICAN-AMERICAN, THIRD.
HISPANIC AND A THIRD WHITE, WE DO HAVE WORK TO PERFORM IN.
TERMS OF HOW WE'' RE DOING WITH OUR GENETICS CYST.
VACCINATION AND ALSO WE HAVE RAISED THAT HAS BEEN.
RECEIVED BY THE HISPANIC AND BLACK AREA.
THOSE ARE.
NOT THE ROUGH THIRDS THAT I JUST LAID OUT IN A PRIOR.
SLIDE. WE HAVE A GREAT DEAL OF FUNCTION TO PERFORM IN PUBLIC WELLNESS,.
HEALTHCARE AND ALSO COMMUNITIES IN REACHING OUR.
HARDER-TO-REACH POPULATIONS TO MAKE CERTAIN THAT THEY, TOO.
ARE SAFEGUARDED VERSUS THE MONKEYPOX. I'' M LOOKING AT. THE TIME. I INTEND TO INVEST JUST A MINUTE TO DISCUSS.
EBOLA, AS I IDENTIFY THAT YOU ARE A CRITICAL PARTNER.
IN OUR EBOLA TASKS. THE FIRST INSTANCE OF THE EBOLA.
SUDAN VIRUS, NOT ZAIRE VIRUS, THE EBOLA SUDAN WAS.
VALIDATED ON SEPTEMBER 20th. THOUGH SOME.
ISSUE IT HAD BEEN CIRCULATING AHEAD OF TIME. WE.
NOW HAVE BREAK OUTS REPORTED IN SEVEN AREAS,.
INCLUDING– I’M SORRY, IN WEB CAM FRIEND LA OR 11 OKAYSES, 90.
VALIDATED, 20 PROBABLE AND 48 FATALITIES. I AM REALLY.
HAPPY WITH FUNCTION THAT WE ARE DOING IN THE CDC.
I WAS– I.
HAD THE TERRIFIC ADVANTAGE OF BEING AT THE CONGO-UGANDA.
BOUNDARY IN THIS PHOTO HEARING ABOUT THE IMPORTANT FUNCTION.
WE'' RE ARE PERFORMING IN GLOBAL WELLNESS SECURITIES, ONE.
HEALTH, ONE CDC FEEDBACK, AND SIMPLY TO ACKNOWLEDGE THAT.
WE HAVE A TEAM OF CDC OF ABOUT 10 PEOPLE, NATION.
OFFICE OF 140 PEOPLE.WE NOW HAVE MORE THAN 20 INDIVIDUALS ON
THE GROUND ENGAGED IN THIS ACTION, AND SO MUCH OF THE
WORK THAT WE DO AT CDC IN PARTNERSHIP WITH THE PUBLIC
HEALTH AS WELL AS PARTNERSHIP WITH HEALTHCARE, IN COLLABORATIONS
WITH COMPANIONS WORLDWIDE THROUGH THE MANAGEMENT
OF UGANDA AND THE MINISTRY OF WELLNESS IN UGANDA IS
SAFETY AND SECURITY FOR ALL OF SUDAN AND CONTAGIOUS HAZARDS
AROUND THE WORLD.
WITH THAT, I WILL CERTAINLY SIMPLY CLOSE BELOW
BY SAYING, WE ARE IN A VARIOUS PHASE OF THIS
PANDEMIC. WE OBSERVED IN REAL TIME A DECOUPLING OF
CASES OF SERIOUS DISEASES. THERE ARE, IN MY MIND, MUCH
WAY TOO MANY AMERICANS PERISHINGS OF COVID, PARTIALLY BECAUSE OF LOW
BOOSTER AND VACCINE UPTAKE. IF I FOUND OUT SOMETHING IN MY
LAST TWO YEARS IN THIS DUTY, ALMOST TWO YEARS IN THIS
FUNCTION, I DON'' T NECESSARILY KNOW WHICH INFECTIOUS OR
NON-INFECTIOUS DANGER WILL CERTAINLY BE THE ONE THAT COMES
KNOCKING ON OUR DOOR AND THAT IT'' S SO CRITICALLY IMPORTANT THAT WE HAVE A ROBUST PUBLIC HEALTH AS WELL AS HEALTH AND WELLNESS TREATMENT FRAMEWORK WORKING IN PARTNERSHIP TO ADDRESS WHATEVER MAY FOLLOW. AS SCIENTIFIC RESEARCH ADVANCES, WE NEED TO ADAPT OUR GUIDANCE AND ALSO SUGGESTIONS TO BALANCE SAFETY AS WELL AS PERFORMANCES OF ALL TREATMENTS. THAT HEALTH HAS TO BE CLEARLY AN VITAL SEAT AT THE TABLE AS WELL AS WE REQUIREMENT TO HAVE THAT ENLIGHTENED BY PUBLIC HEALTH, BASIC SCIENTIFIC RESEARCH AND REAL-WORLD APPLICATIONS.
WE AT PUBLIC HEALTH AND WELLNESS STRIVE TO BE DATA-DRIVEN, ACTION-ORIENTED, TIMELY AND ABOVE ALL, GOOD PARTNERS FOR ALL OF YOU. AGAIN, A.
EXCELLENT ENJOYMENT TO PROVIDE THIS TALK. AND THANK YOU EXTREMELY, VERY AS WELL AS THANK YOU EXTREMELY, EXTREMELY.
MUCH. >> > > MANY THANKS SIGNIFICANTLY, DR. WALENSKY. THAT WAS.
AMAZING. THANK YOU FOR THE TERRIFIC TALK. I DESIRE.
YOU COULD HEAR THE ONLINE APPLAUSE.
[LAUGHTER] WE OBTAINED SEVERAL.
INQUIRIES. WE DON'' T HAVE MUCH TIME SO FORGIVE ME.
GIVEN THAT WE'' RE NOT GOING TO BE ABLE TO TAKE CARE OF ALL. INQUIRIES. THEY ARE WONDERFUL
. I THINK YOU. MAYBE HAVE TIME FOR ONE
>> OR TWO QUESTIONS.> > > PLEASE. > > SO THE FIRST INQUIRY.
I'' LL POSITION TO YOU WAS SENT TO I.D. FELLAS. I THINK IT HAS A GREAT DEAL OF INSIGHT AND ALSO CHALLENGING ON A.
COUPLE VARIOUS POINTS AND I WILL EXPAND THE CONCERN. THE INQUIRY ESSENTIALLY IS, HOW DO WE PERFORM RESEARCH.
ON BOOK VIRUSES LIKE SARS CO-V AND WITH THE RECENT.
FUNCTION AT BOSTON COLLEGE? HOW DO WE PUT SAFEGUARDS.
AROUND THAT RESEARCH STUDY? THE SECONDLY COMPONENT, WITH THOSE.
SAFEGUARDS, HOW DO WE DESCRIBE THAT TO THE LAY.
PUBLIC WHO HAVE ISSUES CONCERNING VIRAL RETREAT?
>> >
> YEAH. I WANTED I HAD AN ANSWER, A WHOLE-HEARTED.
RESPONSE TO THAT CONCERN. THIS IS GOING TO BE JUST ONE OF.
OUR CHALLENGES PROGRESSING. I ASSUME– I RECOGNIZE.
THAT NIH IS LOOKING AT THIS BECAUSE OF WHAT WAS INCREASED.
WITH THE RESEARCH STUDY THAT WAS HAPPENING AT NBU. I.
ACTUALLY THINK WE HAVE TO LOCATE THE COURSE TO BE ABLE TO.
CARRY THIS OUT, TO BE ABLE TO NOT ONLY CONDUCT THE ESSENTIAL.
RESEARCH STUDY TO RESPONSE THE CRUCIAL CONCERNS AND ALSO TO.
COMMUNICATE IT AS WELL AS POSSIBLY WHAT I WILL CERTAINLY DO IS PIVOT AND.
SAY, SEVERAL OF THIS IS REALLY ABOUT THE INTERACTION OF.
THAT STUDY.
SEVERAL OF THIS IS REALLY ABOUT THE.
POLITICIZATION OF GAIN OF FUNCTION RESEARCH IN.
GENERAL. I CAN TELL YOU I HAVE AFFIRMED NOW GREATER THAN.
A DOZEN TIMES ON THE HILLSIDE. I TIN SAY WHENEVER THAT.
INQUIRY HAS POSED TO DR. FAUCI, I'' M RESTING TO HIS.
RIGHT. WE HAD NUMEROUS CONVERSATIONS THAT WHEN.
THOSE POINTS OBTAIN PICKED UP BY THE MEDIA, WHEN THOSE.
POINTS ARE THE EMPHASIS, WE'' RE LOSING THE SIGNIFICANCE OF THE.
INSIGHT– SCIENTIFIC UNDERSTANDING, THE MEDICAL.
COUNTER-MEASURES THAT COULD BE LEARNED AND GAINED,.
RIGHT? EVERY ONE OF THE IMPORTANT THINGS THAT COULD BE FOUND OUT AND ALSO.
OBTAINED. I DON'' T IN FACT HAVE THE SOLUTION. I RECOGNIZE.
THAT THERE ARE LARGE BOARDS THAT ARE LOOKING.
AT THIS REALLY ESSENTIAL INQUIRY. I WEAR'' T THINK. IT ' S BEEN ASSISTED BY THE MOMENT IN REGARDS TO THE.
POLITICIZATION OF IN WHICH WE ARE.
>> > > OKAY. I THINK WITH THAT SAID, WE'' RE AT THE TOP OF THE. HR. SO MANY THANKS, ONCE MORE, DR. WALENSKY.
IT ' S. BEEN JUST AN HONOR AND ALSO An ENJOYMENT TO HAVE YOU EXISTING.
TODAY. IT'' S WONDERFUL TALK SO THANK YOU ONCE ONCE AGAIN. JUSTIN.
>> > > ABSOLUTELY. THANK YOU SO.
MUCH, DR. WALENSKY. THANK MUCH, DR. WALENSKY. THANK.
YOU TO THE WHOLE CDC GROUP FOR ASSISTING TO MAKE THIS.
TAKE PLACE. THANKS TO DR. SIFRI AS WELL AS DR. FRED HAYDEN FOR.
THEIR ONGOING MANAGEMENT WITH THE LECTURE AS WELL AS.
VIROLOGY AS WELL AS EPIDEMIOLOGY AND THANK YOU TO OUR.
INDIVIDUALS EXPECT ANNOUNCEMENTS ON FUTURE.
CLINICAL CENTER HOURS IN MONTHS AHEAD. HAVE A.
WONDERFUL WEEK.
